Portfolio news Archives - Page 6 of 6

Anaveon raises CHF 35 million

Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…

clement05.03.2020

All Portfolio news

Polyneuron raises CHF 22.5 million in Series A financing

Polyneuron Pharmaceuticals, one of our portfolio companies has successfully raised 22.5 million francs in a round of financing. The Basel-based company will use the proceeds…

clement04.03.2020

All Portfolio news

Alentis raises 12.5 million Swiss francs

The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by…

clement03.03.2020

All Portfolio news

T3 Pharma raises over $12 million

T3 Pharma, a spin-off of the University of Basel and one of our portfolio, has raised over $12 million from Boehringer Ingelheim Venture Fund and…

clement02.03.2020

All Portfolio news

Versameb raises 6.4 million Swiss francs

Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its technology platform.…

clement01.03.2020

Portfolio news

T3 Pharmaceuticals wins W.A. de Vigier Award

T3 Pharmaceuticals is among the winners of this year’s W.A. de Vigier Award. The spin-off from the University of Basel is developing a targeted cancer…

clement28.05.2019

Portfolio news

Polyneuron raises CHF 22.5 Million in Series A to advance novel Therapies for Autoimmune Diseases

Leading venture capital firm Sofinnova Partners led the Series A financing, together with New Enterprise Associates, which co-led the round Basel, Switzerland, 28 March 2019–Polyneuron…

clement28.03.2019

Human immune cells can eliminate cancer cells. Anaveon has developed a special antibody to boost the body’s own defense mechanism. The picture shows an electron-microscopic view of one of the immune system’s CD8 killer cells. (Image: NIAID/flickr)

Portfolio news

BaseLaunch backed Anaveon received funding

Onur Boyman, an immunologist working at the University Hospital Zurich and UZH, has joined forces with Andreas Katopodis to establish Anaveon, a BaseLaunch participant. Aiming to translate…

clement20.06.2018

Portfolio news

BaseLaunch accelerated Polyneuron raises new financing

Polyneuron Pharmaceuticals, a BaseLaunch participant, has successfully raised over 3 million Swiss francs in a financing round. The Basel-based pharmaceutical company is developing an active…

clement14.05.2018

Portfolio news

Biotech VCs are backing more rounds and making bigger bets

Biotech is a lot like venture capital. Vast amounts of research, testing and marketing go into a wide range of therapies. But in the end,…

clement10.03.2018

Portfolio news

Anaveon raises CHF 35 million

Polyneuron raises CHF 22.5 million in Series A financing

Alentis raises 12.5 million Swiss francs

T3 Pharma raises over $12 million

Versameb raises 6.4 million Swiss francs

T3 Pharmaceuticals wins W.A. de Vigier Award

Polyneuron raises CHF 22.5 Million in Series A to advance novel Therapies for Autoimmune Diseases

BaseLaunch backed Anaveon received funding

BaseLaunch accelerated Polyneuron raises new financing

Biotech VCs are backing more rounds and making bigger bets

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us